Gefitinib vs Osimertinib: — Making the Decision When Cost Matters

Yes, and this is the plan many oncologists have in mind from the start. When gefitinib stops working, a liquid biopsy or tissue biopsy looks for the T790M mutation. If it is present — and ESMO data identify it as the most common mechanism of acquired resistance to first-generation drugs — osimertinib is the recommended next treatment. This sequence is supported by NCCN and ESMO guidance. The critical thing is that testing happens promptly when your symptoms change or scans show progression, not after a long delay.

A generic drug contains the same active molecule at the same dose and is held to the same bioequivalence standard as the original. CDSCO, the medicines regulator in India, applies this standard at approval. Generic gefitinib from established manufacturers is widely used in Indian oncology practice without clinical concern. If you are uncertain about a specific product your pharmacy is supplying, ask your oncologist or pharmacist to confirm the manufacturer's standing before you start.

The difference is substantial, though prices change and any figure you are given now may shift. Generic gefitinib is among the most affordable targeted therapies for EGFR-mutant lung cancer available in India. Osimertinib is available only as a branded drug and is significantly more expensive per month. Ask your oncology centre or pharmacist for current indicative pricing when you are starting. Some patients access osimertinib through manufacturer patient assistance programmes — ask your oncologist whether there is one you may qualify for.

It can reduce brain metastases in some patients, but its penetration into the brain is substantially lower than osimertinib's. Where brain metastases are present, NCCN and ESMO guidelines prefer osimertinib for this reason. If gefitinib is your current drug and you develop new or worsening headaches, vision changes, weakness, or confusion, contact your team the same day rather than waiting for your next scheduled appointment — these symptoms need prompt assessment.

Both drugs cause similar class effects: skin rash, diarrhoea, dry or itchy skin, and changes around the nail bed. These are common and usually manageable with early support from your team. Osimertinib additionally carries a small risk of effects on heart rhythm and function, so your team may arrange periodic ECGs. Gefitinib requires regular liver function monitoring. On either drug, report new or worsening breathlessness promptly — a rare but serious lung side effect can occur with both, and early reporting is what determines the outcome.

It is entirely reasonable to ask your oncologist to explain the reasoning — why they chose gefitinib for your specific situation, and what the plan is if resistance develops. That conversation may reassure you, or it may prompt a reconsideration. The comparison data show osimertinib has real advantages in CNS penetration and length of first response, and those matter more for some patients than others. Your oncologist's recommendation should take your scan results, your overall situation, and cost realities into account. If you remain uncertain after that conversation, a second opinion from another oncologist is a legitimate next step.